title: Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
abstract: Non-small lung cancer (NSCLC) is a lethal malignancy when diagnosed in advanced stage. The evolution of chemotherapy and the development of agents targeting certain molecular pathways involved in tumor progression improved the prognosis. Nintedanib is a new tyrosine kinase inhibitor, which exerts its activity by blocking VEGF, FGF and PDGF receptors and inhibits the angiogenic signaling by preventing receptor dimerization. Several Phase I and II studies proved its safety and efficacy in diverse solid tumors. In patients with advanced NSCLC, the administration of nintedanib may offer an additional chemotherapy benefit in terms of response rate, progression-free survival and overall survival particularly in patients with adenocarcinoma histology, with manageable toxicity. Here, we present an analytical review of literature regarding nintedanib and we focus on its particular importance in NSCLC treatment.
authors.affiliation: 2nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, 171 Alexandras Av., 11522, Athens, Greece.
authors.forename: John
authors.initials: J
authors.lastname: Syrios
authors.forename: Georgios
authors.initials: G
authors.lastname: Nintos
authors.forename: Vassilis
authors.initials: V
authors.lastname: Georgoulias
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D011379:Prognosis; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D007211:Indoles; D043823:Taxoids; D000077143:Docetaxel; C530716:nintedanib
keywords: adenocarcinoma; angiogenesis; nintedanib; non-small-cell lung cancer; tyrosine kinase inhibitor